iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) was the target of a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 12,424,102 shares, a growth of 11.5% from the April 15th total of 11,137,723 shares. Based on an average daily trading volume, of 3,770,180 shares, the short-interest ratio is presently 3.3 days.

NASDAQ IBB opened at $104.20 on Friday. iShares Nasdaq Biotechnology ETF has a 52-week low of $89.01 and a 52-week high of $122.97.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Neuberger Berman Group LLC boosted its holdings in shares of iShares Nasdaq Biotechnology ETF by 6.0% during the third quarter. Neuberger Berman Group LLC now owns 3,208 shares of the financial services provider’s stock worth $391,000 after purchasing an additional 182 shares during the last quarter. Bank of Montreal Can boosted its holdings in shares of iShares Nasdaq Biotechnology ETF by 21.2% during the fourth quarter. Bank of Montreal Can now owns 356,482 shares of the financial services provider’s stock worth $34,376,000 after purchasing an additional 62,272 shares during the last quarter. Calamos Advisors LLC boosted its holdings in shares of iShares Nasdaq Biotechnology ETF by 1.6% during the fourth quarter. Calamos Advisors LLC now owns 53,805 shares of the financial services provider’s stock worth $5,188,000 after purchasing an additional 865 shares during the last quarter. VERITY Wealth Advisors acquired a new stake in shares of iShares Nasdaq Biotechnology ETF during the fourth quarter worth $1,339,000. Finally, Fisher Asset Management LLC boosted its holdings in shares of iShares Nasdaq Biotechnology ETF by 305.9% during the fourth quarter. Fisher Asset Management LLC now owns 7,659 shares of the financial services provider’s stock worth $739,000 after purchasing an additional 5,772 shares during the last quarter. Institutional investors and hedge funds own 69.34% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “iShares Nasdaq Biotechnology ETF (IBB) Sees Significant Growth in Short Interest” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/ishares-nasdaq-biotechnology-etf-ibb-sees-significant-growth-in-short-interest/3022297.html.

iShares Nasdaq Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Further Reading: Google Finance Portfolio

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.